Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.43 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2738376 | 0.92 | LMNA (0.49) | LMNAEHMT2EHMT1APOBEC3GSMN1; SMN2 | |
| SCHEMBL17253259 | 0.86 | LMNA (0.47) | LMNAEHMT2EHMT1APOBEC3GSMN1; SMN2 | |
| SCHEMBL15777571 | 0.85 | EHMT2 (0.48) | LMNAEHMT2EHMT1APOBEC3GSMN1; SMN2 | |
| SCHEMBL17686497 | 0.85 | LMNA (0.53) | LMNAEHMT2EHMT1APOBEC3GSMN1; SMN2 | |
| SCHEMBL15591524 | 0.85 | LMNA (0.51) | LMNAEHMT2EHMT1APOBEC3GSMN1; SMN2 | |
| SCHEMBL903346 | 0.84 | ALDH1A1 (0.49) | LMNAEHMT2EHMT1APOBEC3GSMN1; SMN2 | |
| SCHEMBL31040491 | 0.84 | ALDH1A1 (0.49) | LMNAEHMT2EHMT1APOBEC3GSMN1; SMN2 | |
| SCHEMBL31040490 | 0.84 | ALDH1A1 (0.49) | LMNAEHMT2EHMT1APOBEC3GSMN1; SMN2 | |
| SCHEMBL844408 | 0.84 | EHMT2 (0.47) | LMNAEHMT2EHMT1APOBEC3GSMN1; SMN2 | |
| SCHEMBL19184631 | 0.84 | LMNA (0.44) | LMNAEHMT2EHMT1APOBEC3GSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317249-A1 | SYNTHETIC METHOD FOR THE PREPARATION OF RHEOLOGICAL MODIFYING POLYMERS AND THE USE THEREOF | POLYANALYTIK INC. (CA) | 2021-10-14 | — | — | US | claimed |
| EP-3824002-A1 | SYNTHETIC METHOD FOR THE PREPARATION OF RHEOLOGICAL MODIFYING POLYMERS AND THE USE THEREOF | Polyanalytik Inc. (CA) | 2021-05-26 | — | — | EP | claimed |
| WO-2020014785-A1 | SYNTHETIC METHOD FOR THE PREPARATION OF RHEOLOGICAL MODIFYING POLYMERS AND THE USE THEREOF | POLYANALYTIK INC. (CA) | 2020-01-23 | — | — | WO | claimed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20210317249-A1 | SYNTHETIC METHOD FOR THE PREPARATION OF RHEOLOGICAL MODIFYING POLYMERS AND THE USE THEREOF | POLYANALYTIK INC. (CA) | 2021-10-14 | — | — | US | disclosed |
| EP-3824002-A1 | SYNTHETIC METHOD FOR THE PREPARATION OF RHEOLOGICAL MODIFYING POLYMERS AND THE USE THEREOF | Polyanalytik Inc. (CA) | 2021-05-26 | — | — | EP | disclosed |
| US-10660970-B2 | Nucleic acid constructs and methods of using the same | GENEVANT SCIENCES GMBH (CH) | 2020-05-26 | — | — | US | disclosed |
| US-10646582-B2 | Block copolymers | GENEVANT SCIENCES GMBH (CH) | 2020-05-12 | — | — | US | disclosed |
| WO-2020014785-A1 | SYNTHETIC METHOD FOR THE PREPARATION OF RHEOLOGICAL MODIFYING POLYMERS AND THE USE THEREOF | POLYANALYTIK INC. (CA) | 2020-01-23 | — | — | WO | disclosed |
| US-8088365-B2 | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution | NEKTAR THERAPEUTICS (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090215988-A1 | Soluble, Degradable Poly(Ethylene Glycol) Derivatives for Controllable Release of Bound Molecules into Solution | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10646582-B2 | Block copolymers | CHMP4B, CD47, EEA1 | LMNA 1251/4885EHMT2 4383/4885EHMT1 4540/4885 |
| US-10660970-B2 | Nucleic acid constructs and methods of using the same | EXOSC5, DIS3, MTREX | LMNA 607/4885EHMT2 3789/4885EHMT1 3986/4885 |
| US-20090215988-A1 | Soluble, Degradable Poly(Ethylene Glycol) Derivatives for Controllable Release of Bound Molecules into Solution | IDE, EGFR, IDUA | LMNA 3903/4885EHMT2 3828/4885EHMT1 3604/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | LMNA 2066/4885EHMT2 2848/4885EHMT1 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.